Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 8/20 | 0.63 |
| ▸ | CA1 | P00915 | 5/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2940371 | 0.83 | CA2 (0.67) | CA2CA1MAPK1USP2MEN1 | |
| SCHEMBL8460512 | 0.79 | CA2 (0.73) | CA2CA1MAPK1USP2MEN1 | |
| SCHEMBL5531843 | 0.79 | CA2 (0.56) | CA2CA1MAPK1USP2MEN1 | |
| SCHEMBL2106254 | 0.78 | CA2 (0.70) | CA2CA1MAPK1USP2MEN1 | |
| SCHEMBL8054453 | 0.78 | CA2 (1.00) | CA2CA1MAPK1USP2MEN1 | |
| SCHEMBL5326388 | 0.78 | CA2 (0.70) | CA2CA1MAPK1USP2MEN1 | |
| SCHEMBL9509870 | 0.76 | CA2 (0.68) | CA2CA1MAPK1USP2MEN1 | |
| SCHEMBL2058687 | 0.76 | CA2 (0.68) | CA2CA1MAPK1USP2MEN1 | |
| SCHEMBL3911707 | 0.76 | CA2 (0.68) | CA2CA1MAPK1USP2MEN1 | |
| SCHEMBL5323183 | 0.76 | CA2 (0.68) | CA2CA1MAPK1USP2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060211603-A1 | Ramoplanin derivatives possessing antibacterial activity | VICURON PHARMACEUTICALS INC. (US) | 2006-09-21 | — | — | US | claimed |
| US-7378551-B2 | Amide compound | KAO CORPORATION (JP) | 2008-05-27 | — | — | US | disclosed |
| US-20070185208-A1 | Amide compound | KAO CORPORATION (JP) | 2007-08-09 | — | — | US | disclosed |
| WO-2007001335-A2 | RAMOPLANIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARMACEUTICALS INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| US-20060211603-A1 | Ramoplanin derivatives possessing antibacterial activity | VICURON PHARMACEUTICALS INC. (US) | 2006-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185208-A1 | Amide compound | H1-0, H1-2, H1-4 | CA2 4332/4885CA1 4192/4885MAPK1 1902/4885 |
| US-20060211603-A1 | Ramoplanin derivatives possessing antibacterial activity | CLSPN, LMAN2, RPN2 | CA2 2359/4885CA1 3211/4885MAPK1 3183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.